Targeted disruption

PEP-Therapy's peptides block specific protein-protein interactions

PEP-Therapy S.A.S. is developing fusion peptides for cancer that block specific intracellular protein-protein interactions, which could be safer than broad inhibitors of the same proteins.

The company's fusion peptides comprise an optimized cell-penetrating peptide that shuttles a short interfering peptide into the cell.

The shuttle is a 12-amino-acid peptide derived from an enzyme in a cattle parasite. The biotech modified the peptide with point mutations to prevent degradation by proteases, which in turn improves in vivo stability and cellular

Read the full 802 word article

How to gain access

Continue reading with a
two-week free trial.